FDA Machine Learning Fellowship
*Applications will be reviewed on a rolling-basis.
Multiple opportunities may be available at the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) in Silver Spring, Maryland and Stanford University/University of California, San Francisco. The participant will likely spend only a small portion of the time in Silver Spring for project acquaintance, mentor establishment, and familiarity but then will continue the experience at Stanford/UCSF (Contingent upon the most current considerations for the Covid-19 pandemic).
The Office of Clinical Pharmacology (OCP) at the U.S. FDA launched the Artificial Intelligence (AI) initiative in 2018 to support the healthcare applications of this technology as an emerging frontier in regulatory decision making. As part of this initiative, OCP partners with the UCSF-Stanford Centers of Excellence in Regulatory Science and Innovation (CERSIs) to offer a one year ORISE opportunity for an interested participant to conduct high impact regulatory science research. This AI fellowship provides the opportunity for an individual to train in collaboration with scientists at both Stanford University/UCSF and the FDA to conduct research that will advance new drug development and promote public health. During participation in this program, the participant will engage in various activities that include but are not limited to the applications of AI/machine learning (ML) for precision medicine, drug development and regulatory science.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time whether virtually, or doing participation both at FDA in the Silver Spring, Maryland, area and at Stanford University/UCSF when the pandemic restrictions end. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.